1. Home
  2. VNOM vs SYRE Comparison

VNOM vs SYRE Comparison

Compare VNOM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VNOM

Viper Energy Inc.

N/A

Current Price

$39.94

Market Cap

7.7B

Sector

Energy

ML Signal

N/A

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

N/A

Current Price

$94.65

Market Cap

8.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VNOM
SYRE
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
8.7B
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
VNOM
SYRE
Price
$39.94
$94.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
20
18
Target Price
$55.45
★ $123.87
AVG Volume (30 Days)
★ 2.0M
823.0K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
★ 6.29%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.99
N/A
Revenue
★ $1,395,000,000.00
N/A
Revenue This Year
$92.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.97
★ N/A
Revenue Growth
★ 62.02
N/A
52 Week Low
$35.27
$24.58
52 Week High
$51.13
$110.64

Technical Indicators

Market Signals
Indicator
VNOM
SYRE
Relative Strength Index (RSI) 38.72 46.80
Support Level N/A $93.28
Resistance Level $45.45 $105.94
Average True Range (ATR) 1.37 5.92
MACD -0.29 -1.13
Stochastic Oscillator 7.99 7.83

Price Performance

Historical Comparison
VNOM
SYRE

About VNOM Viper Energy Inc.

Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: